Subgroup Analysis Can Optimize the Relapse Prediction Cutoff Value for WT1 Expression Following Allogeneic Hematologic Stem Cell Transplantation in Acute Myeloid Leukemia.
High WT1 expression after allogeneic hematologic stem cell transplantation (allo-HSCT) can strongly predict relapse in acute myeloid leukemia (AML). However, the cutoff values obtained were inconsistent. The precise cutoff values may be optimized through subtype analysis, and the RUNX1-RUNX1T1 fusion transcript provides an ideal reference. RUNX1-RUNX1T1 and WT1 transcript levels were simultaneously measured in 1,299 bone marrow samples serially collected from 176 t(8;21) AML patients after receiving allo-HSCTfor. The upper limit of the normal bone marrow WT1 level was 0.6%, previously reported to be the cutoff value for significant relapse prediction in AML as a whole. The cutoff values 0.6%, 1.2%, and 1.8% for WT1 significantly differentiated patients in relapse after allo-HSCT. Nevertheless, both patients with WT1 levels 0.6% to 1.2% and those with levels between 1.2% to 1.8% post-HSCT had a similar cumulative incidence of relapse rates as those with a continuous WT1 level ≤0.6% and both were significantly lower than that of patients with a WT1 level >1.8%. WT1 expression was significantly related to the RUNX1-RUNX1T1 transcript levels at WT1 levels >1.8% but not at levels 0.6% to 1.2% and 1.2% to 1.8%. Therefore, subgroup analysis can optimize the relapse prediction cutoff value for WT1 expression, and a cutoff level of 1.8% more accurately differentiates t(8;21) AML patients in relapse after allo-HSCT than the cutoff level of 0.6%.